Hydroxychloroquine Associated With Lower COVID-19 Mortality: Study

People who received hydroxychloroquine were less likely to die than those who did not, according to a new study.

Just 0.8 percent of patients at a facility in France who received hydroxychloroquine (HCQ) and an antibiotic died, compared to 4.8 percent of patients who did not receive the drug combination, French researchers reported on Nov. 1.

“This study represents the largest single-center study evaluating HCQ-AZ in the treatment of COVID-19. Similarly, to other large observational studies, it concludes that HCQ would have saved lives,” Dr. Didier Raoult, with Aix-Marseille Universite in Marseille, and his co-authors wrote.

The paper was published in the journal New Microbes and New Infections. It was released as a preprint earlier this year, but withdrawn because authors said they have changed their “analytic strategies.”

Mixed Evidence

Dr. Raoult and his co-authors acknowledged that several large randomized trials have found no benefits for HCQ against COVID-19, including a World Health Organization trial. But they said that the largest, funded by the World Health Organization and and United Kingdom government, suffered from “significant methodological problems,” including high dosing during the first 24 hours.

The group also criticized smaller trials with similar findings as underpowered, including a trial in France that was stopped due to enrollment issues.

More on The Epoch Times.